As of 2026-04-03, the Fair Value of Redhill Biopharma Ltd (RDHL) is -10.29 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 0.80 USD, the upside of Redhill Biopharma Ltd is -1,386.75%.
With the market price of 0.80 USD and our fair value calculation, Redhill Biopharma Ltd (RDHL) is not a good investment. Investing in RDHL stocks now will result in a potential loss of 1,386.75%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 5Y Avg | |
| Net income | -76.17 | -97.74 | -71.67 | 23.92 | -8.27 | -45.99 |
| YoY growth | -80.07% | -28.32% | 26.67% | 133.37% | -134.57% | -16.58% |
| Market Cap (mil) | 4.82 |
| P/E | |
| Forward P/E |
| EPS | -2.06 |
| Avg earnings growth rate | -16.58% |
| TTM earnings | -12.40 |